EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook

Xianlu Zhang, Hongwei Jing, Yiyang Wang, Siyu Mu, Xia Wang, Haoyuan Zheng, Yiming Chen, Kaiyuan Wang, Jin Sun, Jianbin Bi, Gejun Zhang

Acta Pharmaceutica Sinica B · 2026-03 · 16 (3) · 1388-1420

DOI: 10.1016/j.apsb.2026.01.019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-03. Verfasst von Xianlu Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Hospital of China Medical University, Shenyang 110000, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 314 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Postdoctoral Program for Innovative Talents, National Natural Science Foundation of China, Liaoning Province Doctoral Start-up Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Membrane-derived biomimetic nanovesicles have emerged as a promising platform in cancer immunotherapy due to their intrinsic biocompatibility, functional plasticity, and capability to modulate immune responses. By integrating various immunotherapeutic agents, including immune checkpoint inhibitors, tumor antigens, and immunostimulatory adjuvants, these vesicles can be engineered to mimic natural immune communication and overcome key barriers in the tumor immune microenvironment. This review summarizes recent advances in the design, functionalization, and application of biomimetic nanovesicles for anti-tumor immunity. We particularly highlight strategies that harness these vesicles to enhance innate and adaptive immune responses, reverse immune suppression, and synergize with existing immunotherapy modalities. Furthermore, we discuss the challenges associated with biosafety, large-scale manufacturing, and clinical translation. Continued innovation in vesicle engineering and immunological modulation will be crucial for transforming biomimetic nanovesicles into viable next-generation cancer immunotherapeutics.

Schlagwörter

Stichwörter der Autor:innen

Biomimetic nanovesiclesCancer immunotherapyDrug deliveryExtracellular vesiclesImmune checkpoint inhibitorImmune modulationMembrane engineeringNanovaccine

Autor:innen und Institutionen

  • Department of Urology, The First Hospital of China Medical University, Shenyang 110000, China.
  • Institute of Urology, China Medical University, Shenyang 110000, China.
  • Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • Department of Neurology, The First Hospital of China Medical University, Shenyang 110000, China.
  • Guangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliated Hospital…
  • Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, S…

Förderung

  • National Postdoctoral Program for Innovative Talents
  • National Natural Science Foundation of China
  • Liaoning Province Doctoral Start-up Foundation
  • China Postdoctoral Science Foundation
  • Department of Education of Liaoning Province
  • Scientific Research Fund of Liaoning Provincial Education Department

Zitieren

APA

Zhang, X., Jing, H., Wang, Y., Mu, S., Wang, X., Zheng, H., Chen, Y., Wang, K., Sun, J., Bi, J., & Zhang, G. (2026). Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook. Acta Pharmaceutica Sinica B, 16(3), 1388-1420. https://doi.org/10.1016/j.apsb.2026.01.019

Vancouver

Zhang X, Jing H, Wang Y, Mu S, Wang X, Zheng H, et al. Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook. Acta Pharmaceutica Sinica B. 2026;16(3):1388-1420. doi:10.1016/j.apsb.2026.01.019

BibTeX
@article{Zhang2026,
  author = {Zhang, Xianlu and Jing, Hongwei and Wang, Yiyang and Mu, Siyu and Wang, Xia and Zheng, Haoyuan and Chen, Yiming and Wang, Kaiyuan and Sun, Jin and Bi, Jianbin and Zhang, Gejun},
  title = {Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {1388--1420},
  doi = {10.1016/j.apsb.2026.01.019}
}
Kostenlos starten →